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Other names: BCSG1 (Breast Cancer-Specific Gene-1 
Protein); Gamma-synuclein; Persyn; PERSYN; PRSN; 
SR; Synoretin 
Location: 10q23.2 
Note: Synuclein-gamma is a member of the synuclein 
family of proteins which are believed to be involved in 
the pathogenesis of neurodegenerative diseases. High 
levels of SNCG have been identified in advanced breast 
carcinomas suggesting a correlation between 




Human SNCG gene consists of five exons that span 
about 5 kbp. The intron 1 contains two closely located 
AP1 recognition sequences. Deletion of these motifs 
greatly diminished the SNCG promoter activity, 
suggesting that AP1 is an important transactivator for 
SNCG transcription SNCG transcription is primarily 
controlled by regulatory sequences located in intron 1 
and exon 1 but not in the 5' flanking region. Synuclein 
expression is regulated predominantly at the level of 




Encoded by human SNCG Gene (Synuclein Family), 
the highly conserved 127-amino acid 13 kD 
cytoplasmic gamma-Synuclein is similar to the amyloid 
protein nonamyloid beta fragment and to alpha-
synuclein and beta-synuclein. The gamma-synuclein 
protein is the least conserved of the synuclein proteins. 
The human gamma-synuclein is 87.7% and 83.8% 
identical to the mouse and rat proteins, respectively, 
which are 4-amino acids shorter. As for the alpha- and
beta-synuclein proteins, the region of highest homol gy 
is the amino-terminal region. The synuclein proteins 
contain several repeated domains that display variations 
of a KTKEGV consensus sequence. This motif, 
repeated six to seven times in the amino-terminal 
portion of the protein, is reminiscent of the alpha-
helical domains of the apolipoproteins and suggests 
lipid binding properties. The very high conservation 
between species for a specific repeated domain of a
particular protein suggests that the repeated domains 
have arisen from the duplication of a single domain 
within an ancestral synuclein gene. Later, this ancestral 
gene may have undergone successive duplications to 
give rise to the three synuclein genes in which the 
repeated domains may still be able to diverge. The third
domain, however, remained absolutely identical, 
KTKEGV, in all genes throughout all species. The 
same type of domain is present in proteins of the rho 
family. However, as of today, the role of these domains 
remains unknown. 
Expression 
Mammalian gamma-synuclein was first identified as 
the so-called Breast Cancer-Specific Gene 1 (BCSG1) 
in a high-throughput direct differential-cDNA-
sequencing screen for markers of breast cancer. 
Northern blot analysis showed that the gene is 
principally expressed in the brain, particularly in the 
substantia nigra. The protein is expressed in the 
peripheral nervous system, mainly in primary sensory 
neurons, sympathetic neurons, and motor neurons. 
Synuclein gamma was also detected in ovarian tumors, 
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and in the olfactory epithelium. A sequence dubbed 
synoretin was independently isolated from ocular 
tissues in a screen for novel proteins regulating 
phototransduction and is now thought to represent the 
bovine ortholog of gamma-synuclein. SNCG is 
expressed in brain, heart, skeletal muscle, ovary, testis, 
colon, spleen, pancreas, kidney and lung. 
Localisation 
The three human synuclein genes are expressed in the 
thalamus, the substantia nigra, the caudate nucleus, and 
the amygdala. Only gamma-synuclein appears strongly 
expressed in the subthalamic nucleus. Although 
gamma-synuclein is not present in senile plaques, Lwy 
bodies or neurofibrillary tangles, a high level of 
gamma-synuclein immunoreactivity is detectable in 
dot-like structures which are characteristic axonal 
lesions in the brains of patients with neurodegenerative 
diseases. SNCG mRNA and gamma-synuclein protein 
were also detected in unstimulated and 
phytohaemagglutinin (PHA)-stimulated cultured 
lymphocytes from peripheral blood of normal donors. It 
has been shown previously by in situ hybridization hat 
SNCG/BCSG1 mRNA is not expressed in normal adult 
breast tissue, but high levels of this mRNA are present 
in advanced infiltrating breast tumours. In 
paraformaldehyde fixed cells, SNCG displayed 
punctuate cytoplasmic staining, a pattern that is usually 
associated with markers of the endoplasmic reticulum 
or vesicular structures. It was also found that gamm -
synuclein was not co-localized with cytokeratin, actin 
or tubulin arrays in these cells. 
Function 
The normal cellular function of gamma-synuclein is as 
yet unknown, but interestingly exogenous expression of 
the protein increases the invasive and metastatic 
potential of breast tumors. The highly conserved N-
terminal region is known to be important for the lipid 
interactions of the synucleins and the highly acidic C-
terminal region has been suggested to possess 
chaperone-like activity, to regulate the aggregation of 
synucleins and to mediate protein-protein interactions. 
It seems that gamma-synuclein plays a role in 
neurofilament network integrity and may modulate 
axonal architecture, also, it may increase the 
susceptibility of neurofilament-H to calcium-dependt 
proteases and may also modulate the keratin network in 
skin. Phosphorylation by GRK5 appears to occur on 
residues distinct from other kinase target residues. 
Synuclein gamma is likely involved in the pathogenesis 
of neurodegenerative diseases and SNCG is expressed 
at very high level in advanced infiltrating breast cancer. 
Sequence analysis suggests that the protein from 
tumour cells (BCSG1) is different from the protein 
expressed in the nervous system (cDNA clones 1 and 
4C) and that coded by the genomic clone W6H. 
Substitution of two lysines by glutamates in BCSG1 
changes the overall charge of the persyn molecule and 
disturbs EKTKEGV repeats that are highly conserved 
in the synuclein family. Such changes should have 
serious consequences for protein structure and function. 
The dual role of SNCG in neurodegeneration and 
malignancy could involve common mechanisms. 
Changes in organization of the cell cytoskeleton are
among the most prominent characteristics of both 
processes. The involvement of gamma-synuclein in 
regulating neurofilament network integrity raises the 
possibility that it may also affect the intermediate 
filament network in malignant breast epithelial cells. 
Homology 
There are currently almost 200 DNA and protein 
sequences in the sequence databases with high 
homology to the synuclein gene or protein. All 
synuclein sequences available to date from Homo 
sapiens, Mus musculus, and Rattus norvegicus can be 
assigned to three distinct protein groups: alpha bet and 
gamma-synuclein. Synuclein proteins have also been 
identified in other organisms: synelfin is the alpha-
synuclein ortholog in Serinus, phosphoneuroprotein 14 
(PNP14) is the beta-synuclein ortholog in Bos taurus, 
and the first synuclein protein described in Torpedo 
californica corresponds to the human gamma-
synuclein. Interestingly, no homologous proteins have 
yet been identified in Escherichia coli, Saccharomyces 
cerevisiae,Caenorhabditis elegans, or Drosophila 
melanogaster. Each of the three family members is 
composed of an N-terminal lipid-binding domain, 
containing a series of 11-residue imperfect repeats, and 
an acidic C-terminal domain. Among the human family 
members, gamma-synuclein 50% identical and 74% 
homologous to alpha- synuclein and 47% identical and 
66% homologous beta-synuclein The highly conserved 
N-terminal region is known to be important for the 
lipid interactions of the synucleins and the highly acidic 
C-terminal region has been suggested to possess 
chaperone-like activity, to regulate the aggregation of 
synuclein and to mediate protein-protein interactions. 
The very high degree of conservation in the lipid-
binding N-terminal domains of all three synucleins 
strongly suggests that both beta and gamma-synuclei 
like alpha-synuclein bind to lipid membranes and adopt 
a highly helical structure. Nevertheless, differences in 
the sequences of the three proteins in both their N-
terminal and C-terminal domains must be responsible 
for those differences that do exist in their indiviual 
functions, as well as for their different roles in disease. 
Mutations 
Note: No tumor-specific mutations of the SNCG gene 
were found in breast tumors and tumor cell lines, but 
two linked polymorphisms in the coding region were 
detected, both in mRNA and in exons III and IV of the 
gene from G243C and T377A. These results reflect the 
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absence of two G--A (and consequently Glu--Lys) in 
tumor cell lines, tumors and control tissues. The above 
mentioned two linked polymorphic sites discriminate 
two alleles of the human persyn gene. The frequencies 
of the two alleles were the same in genomes of breast 
cancer and normal cells (20% G243/T377 and 80% 
C243/A377). Both alleles are transcriptionally active 
and are expressed with similar efficiency in 
heterozygotes. 
Epigenetics 
Sequence analysis identified a CpG island in exon 1 f 
SNCG that contains 15 CpG sites, covering the region -
169 to +81, relative to the translation start codon. CpG 
sites within the CpG island and its vicinity were 
partially and heterogeneously methylated in SNCG-
negative breast cancer cell lines but unmethylated in 
SNCG-positive cells. SNCG expression correlates with 
complete demethylation of the exon 1 region. Specific 
methylation at the CpG sites 2, 5, 7, and 10-15, was
sufficient to block the expression of SNCG gene in 
breast cell culture. Genomic sequencing and 
methylation-specific PCR assays have shown that 
SNCG CpG island is fully methylated in normal tissue  
of liver, esophagus, prostate, cervix, stomach, colon, 
and lung, but only partially methylated in breast ti sue. 
Tumors from these tissues contain completely 
demethylated SNCG. Universal loss of the epigenetic 
control of SNCG gene expression in tumors and further 
demonstrating that the demethylation of SNCG CpG 
island is primarily responsible for the aberrant 
expression of SNCG protein in cancerous tissues have 
suggested an important role of gamma-synuclein-
related epigenectic events in various malignancies. 
Reactivation of SNCG gene expression by DNA 
demethylation is a common critical contributing factor 
to malignant progression of many solid tumors and its 
expression in primary carcinomas is an effective 
molecular indicator of distant metastasis. 
Implicated in 
Note: The possible involvement of gamma-synuclein in 
tumorigenesis first came to light when a gene named 
BCSG1 (Breast Cancer-Specific Gene 1) was shown to 
be overexpressed in advanced infiltrating carcinoma f 
the breast. In fact, BCSG1 and gamma-synuclein 
appear to be the same protein. SNCG protein is highly 
expressed in diversified cancer types, including the
female hormone-sensitive cervical and breast cancers, 
male hormone-sensitive prostate cancer, four cancer 
types of the digestive system, and lung cancer. These 
cancers are currently the leading cause of mortality in 
both men and women. How SNCG induces disease 
progression in different cancer types remains elusive. 
Oncogenic activation of gamma-synuclein contributes 
to the development of breast and ovarian cancer by 
promoting tumor cell survival under adverse conditions 
and by providing resistance to certain chemotherapeutic 
drugs. Overexpression of gamma-synuclein leads to 
constitutive activation of extracellular signal-regulated 
protein kinases ( ERK1 / ERK2 ) and down-regulation 
of c-Jun N-terminal kinase 1 (JNK1) in response to 
environmental stress signals. Cells expressing gamma-
synuclein are significantly more resistant to the 
chemotherapeutic drugs paclitaxel and vinblastine as 
compared with the parental cells. Activation of JNK1 
and its downstream caspase-3 by paclitaxel or 
vinblastine is significantly down-regulated in gamma-
synuclein-expressing cells, indicating that the apoptosis 
pathway activated by vinblastine or paclitaxel is 
blocked by gamma-synuclein. In breast cancer cells, 
SNCG has been shown to act as a chaperon for 
estrogen receptor and stimulate estrogen receptor-a 
signaling pathway that leads to cell proliferation. On 
the other hand, the inhibitory effects of SNCG on 
mitotic checkpoint function are mediated through the
mitotic checkpoint kinase BubR1 and are independent 
of the expression status of estrogen receptor-alpha. T e 
inhibitory effects of SNCG on mitotic checkpoint can 
be overthrown by enforced overexpression of BubR1 in 
SNCG-expressing cells. SNCG intracellularly 
associates with BubR1 together.This observation 
suggests that SNCG expression compromises the 
mitotic checkpoint control by inhibition of the normal 
function of BubR1, thereby promoting genetic 
instability, a recognized and important contributing 
factor in tumorigenesis. Because all synucleins have 
chaperone-like activities, they may interact with 
different proteins in different cellular background. 
Identifications of specific cellular targets of SNCG in 
different tumor types will provide insight to delineate 
its oncogenic functions in human malignancies. 
Breast cancer 
Note: Patients whose tumors expressed SNCG had a 
significantly shorter disease-free survival and overall 
survival. They also had a high probability of death 
when compared with those whose tumors did not 
express SNCG. Multivariate analysis demonstrated that 
SNCG is an independent predictive marker for 
recurrence and metastasis in breast cancer progression. 
SNCG is expected to be a useful marker for breast 
cancer progression and a potential target for breast 
cancer treatment. In one study it has been show that 
responses of 12 breast cancer cell lines to paclitaxe -
induced mitotic arrest and cytotoxicity highly 
correlated with SNCG expression status. SNCG-
positive cells exhibited a significantly higher resistance 
to paclitaxel-induced mitotic arrest than SNCG-
negative cells. Down-regulation of SNCG expression 
directly increased the effectiveness of anti-microtubule 
drug-induced cytotoxicity in breast cancer cells without 
altering cell responses to doxorubicin. These new 
findings suggest that SNCG expression in breast 
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carcinomas is probably a causal factor contributing o 
the poor patient response to paclitaxel treatment. 
Ovarian cancer 
Note: Several studies indicated that SNCG expression 
was not detectable in normal ovarian epithelium but
was highly expressed in the vast majority of advanced 
staged ovarian carcinomas. Eighty-seven percent of 
ovarian carcinomas were found to express at least 1 
type of synuclein, and 42% expressed all 3 synucleins 
(alpha, beta, and gamma) simultaneously. Highly 
punctate gamma synuclein expression was also 
observed in 20% of preneoplastic lesions of the ovary, 
including epithelial inclusion cysts, hyperplastic 
epithelium, and papillary structures, suggesting that 
synuclein gamma up-regulation may occur early in the 
development of some ovarian tumors. Demethylation is 
an important event in abnormal synuclein-gamma 
expression. The methylation pattern in ovarian cancer 
cells is different from that in breast cancer cells. In one 
of the studies that examined SNCG-nonexpressing 
ovarian cancer cells, all of the CpG sites were 
completely methylated instead of selective methylation 
at certain sites shown in breast cancer cells, thereby 
suggesting a tissue-specific methylation pattern. Recent 
studies indicated that the detection of SNCG mRNA in 
tumor-positive tumors was strongly associated with 
demethylation or hypometylation of SNCG gene. 
Methylation status was not correlated with FIGO stage 
or histological type of tumor. Tumor grading was 
strongly associated with methylation status but dueto 
relatively small group of studied samples (43 cases) 
this observation requires further confirmation. Another 
interesting observation was that in 21% of samples both
products of amplification were present and all these 
cases were SNCG mRNA-positive. This observation 
could suggested that partial methylation of SNCG 
probably does not influence on synuclein expression in 
ovarian cancer tissue. Comparison of the methylation 
status of SNCG and the expression of synuclein-
gamma in breast and ovarian cancer cells lines in 
another study indicated a strong correlation between 
hypomethylation of the CpG island and SNCG 
expression in cancer cell lines. The methylation pattern 
in ovarian cancer cells was different from that in breast 
cancer cells. The analyzed CpG sites in ovarian cancer 
cells were all methylated in contrary to a selective 
methylation at certain sites shown in breast cancer 
cells, thereby suggesting a tissue-specific methylaion 
pattern. Moreover, when exon 1 was partially and 
heterogeneously methylated, then SNCG expression in 
breast cancer cells was not detected. 
Lung cancer 
Note: SNCG is not expressed in normal lung tissues, 
but it is highly expressed in lung tumors. It has been 
demonstrated that cigarette smoke extract (CSE) has 
strong inducing effects on SNCG gene expression in 
lung cancer cells through demethylation of SNCG CpG 
island. CSE treatment also augments the invasive 
capacity of cells in an SNCG-dependent manner. These 
new findings demonstrate that tobacco exposure 
induces the abnormal expression of SNCG in lung 
cancer cells through downregulation of expression 
levels of DNA methyltransferases. 
Gastric cancer 
Note: For the gastric cancer cell lines, SNCG mRNA 
expression strongly correlated with demethylation of 
SNCG exon 1 CpG islands. Whereas SNCG was not 
expressed in non-neoplastic gastric mucosal tissues 
obtained at autopsy, partial demethylation was present 
in these tissues. Demethylation occurs before malign nt 
transformation and that only partial demethylation does 
not result in up-regulated SNCG mRNA expression. 
Thus, it appears that partial SNCG demethylation ca 
occur in normal gastric mucosa, which then extends i  
some cases to become to fully demethylated, resulting 
in up-regulated SNCG mRNA expression. 
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